Review Article
Anticoagulation for Atrial Fibrillation: Is This the End of Warfarin? Not Just Yet
Table 3
Showing the relative pharmacokinetics of the novel oral anticoagulants.
| | Dabigatran | Rivaroxaban | Apixaban |
| Target | Thrombin | Factor Xa | Factor Xa | Dose | Twice daily | Once daily | Twice daily | Half-life in hours | 12–17 | 5–9 (but effect last for 24 hours) | 12 | Renal excretion | 80% | 25% | 33% | Hepatic excretion | 20% | 75% | 67% |
|
|